Biophage PharmaInc.

Biophage Pharma Inc. is a biopharmaceutical company focused on developing phage-based technologies for the detection and management of pathogenic bacteria. It is dedicated to the development and commercialization of phage-based therapies to manage (prevent or reduce) bacterial contamination in environments, humans, or animals (such as E. coli and Salmonella); and PVI, a bio-agent countermeasure focused on anthrax infection. The company also develops and sells portable biosensors, such as the PDS biosensor for sensitive bacterial detection; BacTrapping for isolating and specifically enriching bacteria from raw samples; a phage-based microbial system for detecting live bacteria; and a surface plasmon resonance biosensor for detecting slow-growing microorganisms and viruses. Biophage Pharma Inc. was founded in 1995 and is headquartered in Montreal, Canada. As of March 20, 2016, Biophage Pharma Inc. operates as a subsidiary of Phagelux Canada Inc.